Miniatura

Fitxers

SasamotoN.pdf (555.93 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2019-11-26

Llicència de publicació

cc by (c) Sasamoto, Naoko et al., 2019
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/168024

Development and validation of circulating CA125 prediction models in postmenopausal women

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1186/s13048-019-0591-4

Resum

Background Cancer Antigen 125 (CA125) is currently the best available ovarian cancer screening biomarker. However, CA125 has been limited by low sensitivity and specificity in part due to normal variation between individuals. Personal characteristics that influence CA125 could be used to improve its performance as screening biomarker. Methods We developed and validated linear and dichotomous (>= 35 U/mL) circulating CA125 prediction models in postmenopausal women without ovarian cancer who participated in one of five large population-based studies: Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO, n = 26,981), European Prospective Investigation into Cancer and Nutrition (EPIC, n = 861), the Nurses' Health Studies (NHS/NHSII, n = 81), and the New England Case Control Study (NEC, n = 923). The prediction models were developed using stepwise regression in PLCO and validated in EPIC, NHS/NHSII and NEC. Result The linear CA125 prediction model, which included age, race, body mass index (BMI), smoking status and duration, parity, hysterectomy, age at menopause, and duration of hormone therapy (HT), explained 5% of the total variance of CA125. The correlation between measured and predicted CA125 was comparable in PLCO testing dataset (r = 0.18) and external validation datasets (r = 0.14). The dichotomous CA125 prediction model included age, race, BMI, smoking status and duration, hysterectomy, time since menopause, and duration of HT with AUC of 0.64 in PLCO and 0.80 in validation dataset. Conclusions The linear prediction model explained a small portion of the total variability of CA125, suggesting the need to identify novel predictors of CA125. The dichotomous prediction model showed moderate discriminatory performance which validated well in independent dataset. Our dichotomous model could be valuable in identifying healthy women who may have elevated CA125 levels, which may contribute to reducing false positive tests using CA125 as screening biomarker.

Matèries

Càncer d'ovari, Menopausa, Marcadors bioquímics

Matèries (anglès)

Ovarian cancer, Menopause, Biochemical markers

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
<b>Publicacions de projectes de recerca finançats per la UE</b>

Citació

SASAMOTO, Naoko, BABIC, Ana, ROSNER, Bernard a., FORTNER, Renée t., VITONIS, Allison f., YAMAMOTO, Hidemi, FICHOROVA, Raina n., TITUS, Linda j., TJØNNELAND, Anne, HANSEN, Louise, KVASKOFF, Marina, FOURNIER, Agnès, MANCINI, Francesca romana, BOEING, Heiner, TRICHOPOULOU, Antonia, PEPPA, Eleni, KARAKATSANI, Anna, PALLI, Domenico, GRIONI, Sara, MATTIELLO, Amalia, TUMINO, Rosario, FIANO, Valentina, ONLAND-MORET, N. charlotte, WEIDERPASS, Elisabete, GRAM, Inger t., QUIRÓS, José ramón, LUJÁN BARROSO, Leila, SÁNCHEZ, Maria jose, COLORADO-YOHAR, Sandra, BARRICARTE, Aurelio, AMIANO, Pilar, IDAHL, Annika, LUNDIN, Eva, SARTOR, Hanna, KHAW, Kay-tee, KEY, Timothy j., MULLER, David c., RIBOLI, Elio, GUNTER, Marc j., DOSSUS, Laure, TRABERT, Britton, WENTZENSEN, Nicolas, KAAKS, Rudolf, CRAMER, Daniel w., TWOROGER, Shelley s., TERRY, Kathryn l.. Development and validation of circulating CA125 prediction models in postmenopausal women. _Journal Of Ovarian Research_. 2019-11-26. Vol. 12, núm. 116. [consulta: 25 de gener de 2026]. [Disponible a: https://hdl.handle.net/2445/168024]

Exportar metadades

JSON - METS

Compartir registre